Abstract 594P
Background
MET alteration, as promising rare target, plays the key role in the development of NSCLC. However, the treatment pattern and efficacy for Chinese NSCLC patients (pts) with MET alteration in real-world setting is limited. Here, we report the treatment pattern and clinical outcome in Chinese NSCLC pts with MET alteration.
Methods
We performed a retrospective, multicenter study in NSCLC pts with MET alteration between Jul. 2021 and Sep. 2022 in China. Patient characteristics, gene profile, and treatment pattern were collected. The objective response rate (ORR) and time to treatment failure (TTF) were analyzed.
Results
202 NSCLC pts with MET alteration were collected. 117 MET exon 14 skipping mutation (MET ex14m) and MET amplification (amp) (MET NGS GCN≥3.5) pts with subsequent efficacy assessment and follow-up data were included for analysis. The ORR of pts with MET ex14m received 1L savolitinib (savo mono), other MET inhibitor (METi) and chemotherapy (chemo)-based regimen were 56.3%, 16.7%, 36.3%, respectively. The ORR of pts with de novo MET amp received savo, other METi, and chemo-based regimen as 1st-line therapy were 66.7%, 0, 20%, respectively. The ORR of post EGFR/ALK-TKI resistance pts with MET amp (resistant MET amp) received savo mono, savo plus osimertinib (osi), other METi and chemo-based regimen were 12.5%, 43.8%, 0, 14.2%, respectively. (Table) Median TTF of 1L savo mono in pts with MET ex14m was 12.6months and median TTF of savo plus osi in pts with resistant MET amp was 11.3 months. Savo discontinuation due to adverse events occurred in MET ex14m, de novo MET amp and resistant MET amp pts were 18.7%, 33.3%, and 7%, respectively. The safety profile of savo were similar to previously reported data. Table: 594P
The ORR result in the analysis
| MET ex14m (n=44) | De novo MET amp (n=16) | Resistant MET amp (n=57) | |||||
| n | ORR | n | ORR | n | ORR | ||
| 1L | Savo | 16 | 56.3% | 3 | 66% | NA | |
| Other METi | 6 | 16.7% | 3 | 0% | |||
| Chemo | 22 | 36.3% | 10 | 20% | |||
| 2L+ | Savo | 14 | 42.8% | 2 | 50% | 8 | 12.5% |
| Savo+osi | 2 | 50% | 2 | 50% | 32 | 43.8% | |
| Other METi | 3 | 0 | 0 | NA | 3 | 0 | |
| Chemo | 23 | 26.1% | 14 | 28.5% | 14 | 14.2% |
Conclusions
The real-world analysis results showed the promising clinical benefit of savo in NSCLC pts with MET alterations and the acceptable safety. Follow-up of these pts are still ongoing.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
392TiP - A prospective phase II study of individualized adjuvant therapy in patients with locally advanced hypopharyngeal cancer after neoadjuvant therapy
Presenter: Juyi Wen
Session: Poster Display
Resources:
Abstract
397P - Comparison between Y-site co-infusion versus standard dexamethasone for preventing hypersensitivity reactions from oxaliplatin administration: A randomized controlled trial
Presenter: jarearnjit Phavirunsiri
Session: Poster Display
Resources:
Abstract
398P - Evaluation of the effectiveness of denosumab therapy giant cell tumor of the pelvis
Presenter: Abbos Nurjabov
Session: Poster Display
Resources:
Abstract
399P - Long-term outcomes of patients with gastric cancer who received the best supportive care without any anticancer treatment
Presenter: Yohei Arihara
Session: Poster Display
Resources:
Abstract
401TiP - Oral opioid vs intravenous patient-controlled analgesia (PCA) with hydromorphone bolus-only or continuous infusion to maintain analgesia for severe cancer pain: A randomized phase III trial
Presenter: Cheng Huang
Session: Poster Display
Resources:
Abstract
407P - K-TrackTM: A streamlined personalized assay to detect molecular residual disease in solid tumors
Presenter: Nam Vo
Session: Poster Display
Resources:
Abstract
408P - Increased EGFR and MET expression and corresponding tumor microenvironment (TME) change in hepatocellular carcinoma (HCC) tissues after sorafenib (Sora) treatment
Presenter: Chia Jui Yen
Session: Poster Display
Resources:
Abstract
410P - Systematic evaluation of cell-free DNA fragmentation patterns for cancer diagnosis and enhanced cancer detection through integration of multiple fragmentations
Presenter: Xiangy-Yu Meng
Session: Poster Display
Resources:
Abstract
412P - Multiplex digital spatial profiling (DSP) of protein reveals distinct immune and molecular phenotypes in hepatocellular carcinoma
Presenter: Chia Jui Yen
Session: Poster Display
Resources:
Abstract
413P - Clinical utility of advanced features provided by circulating tumor DNA-based comprehensive genomic profiling
Presenter: Young-gon Kim
Session: Poster Display
Resources:
Abstract